A Randomized, 24-week, Controlled, Open Label, Parallel Arm, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Type 2 Diabetes Patients, Inadequately Controlled on Basal Insulin With or Without Metformin
Phase of Trial: Phase III
Latest Information Update: 25 Jan 2019
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine; Insulin glulisine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LixiLan-India
- Sponsors Sanofi
- 26 Jun 2018 Planned End Date changed from 1 Jun 2019 to 30 Aug 2019.
- 26 Jun 2018 Planned primary completion date changed from 1 Jun 2019 to 30 Aug 2019.
- 15 Jun 2018 Status changed from not yet recruiting to recruiting.